Navigation Links
Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder
Date:11/2/2007

HOUSTON, LONDON and RESEARCH TRIANGLE PARK, N.C., Nov. 2 /PRNewswire/ -- Fabre-Kramer Pharmaceuticals Inc. (FKP) and GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has issued a not approvable letter for the new drug application for gepirone extended- release (ER) tablets, submitted for the treatment of adults with major depressive disorder.

The FDA had previously reviewed Phase I through III clinical data involving gepirone ER. In June 2004, the FDA requested an additional positive short-term trial in order to consider gepirone ER for approval as a new antidepressant treatment. Subsequently, FKP successfully conducted a trial in patients with major depressive disorder to respond to the FDA request for an additional positive pivotal study.

Those results were submitted to the FDA in May 2007. The not approvable letter issued today is based on the FDA review of those additional results along with other newly submitted and previously submitted data.

Fabre-Kramer and GlaxoSmithKline entered an agreement in February of this year for collaboration on the worldwide development and commercialization of gepirone extended-release tablets. Fabre-Kramer and GSK are evaluating the response from the FDA to determine appropriate next steps.

About Fabre-Kramer Pharmaceuticals

Fabre-Kramer Pharmaceuticals, headquartered in Houston, Texas, is engaged in acquiring, developing and commercializing psychotropic drugs that have significant market potential. In addition to gepirone ER, Fabre-Kramer has 10 other compounds in various stages of development for indications including depression, anxiety, schizophrenia, Parkinson's disease and insomnia. For more information,
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  MiMedx Group, Inc. (NASDAQ: ... utilizing human amniotic tissue and patent-protected processes to ... the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, ... and corrected the multiple inaccuracies in the press ... regarding the recent rulings from the Patent Trial ...
(Date:8/27/2015)...  Hill-Rom Holdings, Inc., (NYSE: HRC ) invites ... Morgan Stanley Global Healthcare Conference on September 16, 2015, ... to listen to the live discussion via the internet ... https://cc.talkpoint.com/morg007/091615a_ae/?entity=49_UCJPU8N . A recorded replay of ... conclusion of the live event and accessible via the ...
(Date:8/27/2015)... 27, 2015 Major pharmaceutical and medical device companies ... conference in Philadelphia on Oct. 20, ... Tom Hagy of HB Litigation Conferences has announced. ... website at http://litigationconferences.com/?p=31886 The program is ... & Mahoney and Michelle Hart Yeary of Dechert ...
Breaking Medicine Technology:MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 2Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 3
... Systems ( http://www.dcmsys.com ), healthcare IT company and teleradiology ... the Vendor Neutral Archive (VNA) vendor of choice by ... Dicom Systems, VNA works with any existing ... current storage to your PACS archive at any time, ...
... LANSING, Mich., Jan. 16, 2012  Neogen Corporation (NASDAQ: ... detect precise amounts of the mycotoxin zearalenone in grain ... wide variety of reproductive problems if eaten by livestock. ... to the company,s unequaled line of simple, quick, and ...
Cached Medicine Technology:ONRAD, Inc. Chooses Dicom Systems' Vendor Neutral Archive 2Neogen Develops Simple, Precise Test for Mold Toxin Zearalenone 2
(Date:8/27/2015)... ... 27, 2015 , ... In mid-May, Logistics Trust, Inc. (“Logistics ... launch of its Doobster platform, a HIPAA-compliant mobile application that allows medical marijuana ... phones and tablets. Well, Doobster, “The App That Delivers!” is here! ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... Summit , scheduled for October 27-29, 2015 in San Jose, CA. The ... will primarily focus on the void that exists where battery development and energy ...
(Date:8/27/2015)... ... ... In addition to its existing Doctor of Philosophy in Leadership and Doctor of ... campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor of Nursing Practice ... the highest level of clinical nursing practice. , “Our vision is to graduate ...
(Date:8/27/2015)... ... ... Hospital North Pinellas, located at 1395 South Pinellas Avenue in Tarpon Springs, will open a ... be located at US Highway 19 North and Highlands Boulevard, less than eight miles from ... the project is slated to begin in September 2015. , The new 24-bed ...
(Date:8/27/2015)... ... August 27, 2015 , ... NetDimensions is once again named ... the platforms required not only to effectively deliver, curate and administer great programs, but ... Inc. , For six consecutive years, NetDimensions has maintained its position on this ...
Breaking Medicine News(10 mins):Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3
... estimate that fully 95 percent of our DNA represents ... the journal Cell researchers at The Wistar ... the discovery of the ability of long non-coding RNA ... long ncRNA molecules may represent so-called gene enhancer elementsshort ...
... used as a marker of health and well-being in unborn ... currently available to differentiate between a small, healthy fetus and ... significant limitations. What if they were improved? Would it save ... need medical intervention because their fetuses might just be small ...
... Fox Foundation for Parkinson,s Research announced awards totaling approximately ... pre-clinical therapeutic development projects. The funding includes $2.5 million ... Intervention Awards, one of the Foundation,s Edmond J. Safra ... the 2010 Clinical Intervention Awards are: , Charlotte ...
... Oct. 6, 2010 A set of proteins found ... way to diagnose Alzheimer,s disease, researchers at UT Southwestern Medical ... An analysis of the proteins, plus a clinical exam, ... percent accurate in ruling it out in people without the ...
... HealthDay Reporter , TUESDAY, Oct. 5 (HealthDay News) -- ... received ,hands-only, cardiopulmonary resuscitation (CPR) from a bystander were ... received no CPR or conventional CPR with mouth-to-mouth breathing. ... only is ,hands-only, CPR -- in which the rescuer ...
... Mozes HealthDay Reporter , TUESDAY, Oct. 5 (HealthDay ... apnea can subtly alter the shape of a patient,s face ... treatment, called continuous positive airway pressure (CPAP) can help relieve ... found possible craniofacial change [as a result of] long-term CPAP ...
Cached Medicine News:Health News:Wistar researchers discover new class of objects encoded within the genome 2Health News:Wistar researchers discover new class of objects encoded within the genome 3Health News:MFM researcher earns $3.7M NIH grant to study preterm birth 2Health News:MJFF announces over $10 million in funding for clinical and pre-clinical PD research 2Health News:Blood test could diagnose Alzheimer's disease, UT Southwestern researchers find 2Health News:'Hands-Only' CPR May Work Best for Cardiac Arrest 2Health News:'Hands-Only' CPR May Work Best for Cardiac Arrest 3Health News:'Hands-Only' CPR May Work Best for Cardiac Arrest 4Health News:Sleep Apnea Mask May Cause Subtle Facial Changes 2Health News:Sleep Apnea Mask May Cause Subtle Facial Changes 3
... and negative whole blood control to test ... solubility tests and hemoglobin electrophoresis. Sickle-Chex is ... manufacturers' solubility kits. Sickle-Chex is packaged in ... vial dispenses an accurate sample volume. No ...
... three-part differential control assayed for all parameters on ... Series, AcT/AcT diff/AcT diff2, MD Series and ONYX ... 1800; ABX Micros 60; and Diatron Abacus and ... stability of 30 days and a six-month closed-vial ...
... Cell-Chex Auto is a whole blood ... of hematology instruments that measure automated blood ... The assay provides total RBC and WBC ... and Sapphire, Beckman Coulter LH750/LH 755 (levels ...
iSleep 20i is an advanced high performance CPAP with outstanding self-adjusting i‑technology....
Medicine Products: